By Dr Charlotte Rose Lemech

Book Chapters

Lemech CR; Kristeleit R; Arkenau HT, 2011, 'Novel Oncology Drug Development Strategies in the Era of Personalised Medicine', in Kapetanovic IM (ed.), Drug Discovery and Development - Present and Future

Journal articles

Liu J; Farrow M; Hsing SS; Cosman R; Lemech CR; Teng C; Pal A; Nindra U; Parsonson AO; Park JJW; Rodrigues A; Chan WY; Wei J; Cohen J; Underhill CR; Brungs D; Hui M; Nagrial A; Jain S; Joshua AM, 2026, 'Network Integrated Platform for Clinical Trials Navigation from the New South Wales Early Phase Clinical Trials Alliance.', Clin Cancer Res, http://dx.doi.org/10.1158/1078-0432.CCR-26-0733

Liu J; Farrow M; Hsing S; Cosman R; Lemech CR; Teng C; Pal A; Nindra U; Parsonson A; Park JJW; Rodrigues A; Chan W; Wei J; Cohen J; Underhill C; Brungs D; Hui M; Nagrial A; Jain S; Joshua AM, 2026, 'Abstract A056: Network-integrated clinical trial navigation with ctDNA profiling improves early-phase trial access: Final results from the PANNA-COTA study', Clinical Cancer Research, 32, pp. A056 - A056, http://dx.doi.org/10.1158/1557-3265.d32026-a056

Tran B; Voskoboynik M; Kim SW; Lemech C; Carcereny E; Rha SY; Ahn MJ; Felip E; Lee KH; Castañón E; Yang JCH; Ascierto PA; Pulla MP; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im SA, 2026, 'Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody', Clinical Cancer Research, 32, pp. 2850 - 2864, http://dx.doi.org/10.1158/1078-0432.CCR-25-3447

Wang S; Lemech CR; Li N; Wang N; Hu X; Zhang J; Morris MF; Mao W; Jiang H; Zhang F, 2026, 'BL0020, a novel tumor microenvironment (TME)-targeting nano-mediated polypeptide-drug conjugate (NMPDC), in patients with advanced solid tumors: Updated results from the small cell lung cancer (SCLC) subset of a phase 1 study.', Journal of Clinical Oncology, 44, pp. 8095 - 8095, http://dx.doi.org/10.1200/jco.2026.44.16_suppl.8095

Yap TA; Lemech CR; Lau PKH; Coward JIG; Ameratunga M; Luen SJ; Patnaik A; Call JA; Hamilton EP; Wang H; Hunder NNH; Ma S; Smith A; Bansal A; Ayers B; Boyd-Kirkup JD; Ingram P; Lynce F, 2026, 'Phase 1/2 study of CLIO-8221, a HER2-targeted, dual-payload exatecan and ATR inhibitor antibody-drug conjugate (ADC) in patients with advanced HER2-expressing solid tumors.', Journal of Clinical Oncology, 44, http://dx.doi.org/10.1200/jco.2026.44.16_suppl.tps3162

Nguyen J; Nindra U; Tang J; Zwieky W; Hong JH; Hong M; Descallar J; Killen A; Cooper A; Wilkinson K; Pal A; Teng C; Roohullah A; Wei J; Ng W; Lemech C; Chua W, 2026, 'Measuring What Matters: RECIST Response Does Not Predict HRQoL in Early-Phase Clinical Trials', Cancers, 18, http://dx.doi.org/10.3390/cancers18081242

Varkaris A; Lipsyc-Sharf M; Barve M; Oprychal M; Giordano A; Hamilton E; Rodon J; Jhaveri K; Kaklamani V; Lemech C; Wu L; Shah RM; Rhee J; Ben Y; Luen SJ, 2026, 'Abstract PS5-07-06: BREAKER-101: a phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-10203 in patients with advanced solid tumors', Clinical Cancer Research, 32, http://dx.doi.org/10.1158/1557-3265.sabcs25-ps5-07-06

Liu X; Kuang X; Lemech C; Liu Z; Ding J; Zhou X; Liu X; Wang Y; Liao H; wang W, 2026, 'P-111. Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Siltartoxatug, A First-in-Class Anti-Tetanus Monoclonal Antibody: Results of Two Phase I Trials in Australian and Chinese Healthy Adults', Open Forum Infectious Diseases, 13, http://dx.doi.org/10.1093/ofid/ofaf695.339

Lemech C; Xu R-H; Ruan D; Parsonson A; Joubert W; Shinde R; Bhave P; Xue J; Gandhi N; Rasco D; Liu H; Gao Y; Xuefeng F; Zhang B; Xing X; Liu S-H; Meng X, 2026, '112P Phase I study of AMT-676, an anti-CDH17 antibody-drug conjugate, in patients with advanced CRC and other GI tumors', Annals of Oncology, 37, pp. S44 - S44, http://dx.doi.org/10.1016/j.annonc.2026.05.113

Zhou C; Wang B; Teng C; Yang H; Piha-Paul SA; Richardson G; Malalasekera A; Sun Y; Wang W; Liu J; Shi Y; Zhan X; Lemech C, 2025, 'A phase Ia study of a novel anti-HER2 antibody–drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors', Journal of Translational Medicine, 23, http://dx.doi.org/10.1186/s12967-024-05985-z

Thoms JAI; Yan F; Hampton HR; Davidson S; Joshi S; Saw J; Sarowar CH; Lim XY; Nunez AC; Kakadia PM; Bhuyan GS; Zou X; Nguyen M; Ghodousi ES; Koch FC; Vafaee F; Thompson IR; Karimi MM; Pickford R; Raftery MJ; Hough S; Buckland G; Bailey M; Ghodke Y; Absar N; Vaughan L; Pasalic L; Fong CY; Kenealy M; Hiwase DK; Stoddart RI; Mohammed S; Lee L; Passam FH; Larsen SR; Spring KJ; Skarratt KK; Rebeiro P; Presgrave P; Stevenson WS; Ling S; Tiley C; Fuller SJ; Roncolato F; Enjeti AK; Hoenemann D; Lemech C; Jolly CJ; Bohlander SK; Curtis DJ; Wong JWH; Unnikrishnan A; Hertzberg M; Olivier J; Polizzotto MN; Pimanda JE, 2025, 'Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs', Nature Communications, 16, http://dx.doi.org/10.1038/s41467-025-59796-x

Nindra U; Tang J; Hong JH; Descallar J; Hong M; Killen A; Dubey P; Attaullah J; Scott G; Cooper A; Wilkinson K; Pal A; Teng C; Roohullah A; Wei J; Ng W; Lemech C; Chua W, 2025, 'Prospective assessment of health-related quality of life in early phase oncology clinical trials: PEARLER', Jnci Cancer Spectrum, 9, http://dx.doi.org/10.1093/jncics/pkaf108

Nindra U; Tang J; Hong JH; Descallar J; Hong M; Killen A; Dubey P; Attaullah J; Scott G; Cooper A; Wilkinson K; Pal A; Teng C; Roohullah A; Wei J; Ng W; Lemech C; Chua W, 2025, 'Assessing Patient-Reported Financial, Social, and Time Toxicity in Early-Phase Cancer Clinical Trials in Australia Through a Prospective Multicenter Nonrandomized Cohort Study', JCO Oncology Practice, 3, pp. 1 - 1, http://dx.doi.org/10.1200/OP-25-00412

Kang E; Kim D; Hwang S; Lemech C; Wharton J; Lee Y; Yoo HW; Lee BH, 2025, 'A Randomized, Double-Blind, 2-Treatment, 2-Period, Crossover Phase 1 Study to Compare the Pharmacokinetics, Safety and Tolerability of 60 IU/Kg of Abcertin and Cerezyme in Healthy Volunteers Following a Single Intravenous Administration', Molecular Genetics and Genomic Medicine, 13, http://dx.doi.org/10.1002/mgg3.70111

Nindra U; Tang J; Hong JH; Descallar J; Hong M; Killen AJ; Cooper AJ; Wilkinson KJ; Pal A; Teng C; Roohullah A; Wei J; Ng WL; Lemech CR; Chua W, 2025, 'Financial, social and time toxicity in early-phase cancer clinical trials: The PEARLER study.', JOURNAL OF CLINICAL ONCOLOGY, 43, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.11119

Lemech CR; Cosman R; Humphries TG; Kichenadasse G; Richardson GE; Nagrial A; Teng C; Liu J; Joshua AM; Cohen H; Mo J; Harvey K; Zhang H; Ling Z; King N; Barnett M; Cioffi M; Maurer MA; Getts D; Swarbrick A, 2025, 'First-in-human mRNA CAR therapy: Correlative biomarker analysis from the MT-302 phase 1 study targeting TROP2 in patients with advanced epithelial tumors.', Journal of Clinical Oncology, 43, pp. 2591 - 2591, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.2591

Lemech CR; Sun Y; Nagrial A; Wu X; Morris MF; Ning F; Yang J; Pan Y; Cai J; Lu P; Zhang T; Qiu F; Hu C; Zhang M; Liu Z; Han G; Nie J; Teng C; Zhou H; Day D, 2025, 'IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with HER2-positive breast cancer (BC) and other solid tumors: Updates from a phase 1 study.', JOURNAL OF CLINICAL ONCOLOGY, 43, pp. 1029 - 1029, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.1029

Nindra U; Hong JH; Tang J; Descallar J; Hong M; Killen AJ; Cooper AJ; Wilkinson KJ; Pal A; Teng C; Roohullah A; Wei J; Ng WL; Lemech CR; Chua W, 2025, 'Prospective assessment of health-related quality of life in early phase clinical trials.', JOURNAL OF CLINICAL ONCOLOGY, 43, pp. 11118 - 11118, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.11118

Atkinson VG; Brenner W; Brown JT; Cabezón-Gutiérrez L; Gajate P; Kim ST; Lee J; Lemech C; Margolin KA; Moreno I; Moreno V; Oh D-Y; Oliva IG; Park JJ; Shue H; Twardowski P; Winer I; Chisamore MJ; Prawira A; Merchant F; Coello M; To MD; Merchant R; Yavari A; Ascierto PA, 2025, 'Abstract CT047: Interim results from the phase 1/2 ABILITY-1 study of a long-acting ‘beta-enhanced not-alpha’ IL-2 superkine in patients with advanced solid tumors', Cancer Research, 85, pp. CT047 - CT047, http://dx.doi.org/10.1158/1538-7445.am2025-ct047

Lu S; Lemech C; Abed A; Powderly J; Liu SV; Li Z; Jiang L; Gu W; Liu Q; Fang L; Qiu Y; Shi R; Liu Y, 2025, 'Abstract CT121: A phase 1/2a, multicenter, open-label, first in human study of a bispecific ADC targeting B7H3 and PDL1 (DB-1419) in advanced or metastatic solid tumors', Cancer Research, 85, pp. CT121 - CT121, http://dx.doi.org/10.1158/1538-7445.am2025-ct121

Tran B; Frentzas S; Lemech CR; Millward M; Day D; Desai J; Latifi A; Wabnitz P; Kearney P; Galkin AV, 2025, 'Abstract 5850: AXA-042, a systemically administered TLR2/6 agonist, demonstrates innate immune engagement and Th1 polarization in patients with advanced solid tumors', Cancer Research, 85, pp. 5850 - 5850, http://dx.doi.org/10.1158/1538-7445.am2025-5850

Nindra U; Tang J; Hong JH; Hong M; Teng C; Wei J; Killen A; Cooper A; Wilkinson K; Ng W; Lemech C; Chua W; Pal A, 2025, 'Evaluating patient diversity in early phase clinical trials in Australia through a prospective multicenter nonrandomized cohort study', Jnci Cancer Spectrum, 9, http://dx.doi.org/10.1093/jncics/pkaf035

Song Y; Xie L; Zhang Y; Wu H; Pratyush G; Huang H; Cen H; Guo Y; Fan L; Li Y; Li M; Sun X; Liang X; Lemech C; Wang J; Zhu X; Li F; Dai H; Shi Q; Yang JJ, 2025, '1316eTiP A phase Ib trial of CS5001 (ROR1-ADC) as a single agent and in combination with systemic therapies in patients with advanced solid tumours and lymphomas', Annals of Oncology, 36, pp. S766 - S767, http://dx.doi.org/10.1016/j.annonc.2025.08.1947

Wang S; Lemech C; Li N; Wang N; Hu X; Zhang J; Morris M; Mao W; Jiang H; Zhang F, 2025, '2780P BL0020, a novel targeting tumor microenvironment (TME) nano-mediated polypeptide-drug conjugate (NMPDC), in patients with advanced solid tumors: Results from a phase I study', Annals of Oncology, 36, pp. S1380 - S1380, http://dx.doi.org/10.1016/j.annonc.2025.08.3391

Lemech CR; Joubert WL; Parsonson AO; Xu R-H; Shinde R; Bhave P; Xue J; Huang Y; Meng X; Liu S-H, 2025, 'A phase 1, first-in-human study of AMT-676, an anti-CDH17 antibody-drug conjugate, in patients with advanced gastrointestinal tumors.', Journal of Clinical Oncology, 43, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.tps3161

Yap TA; Lemech C; Voskoboynik M; Millward M; Hafez M; Tam L; Subbiah V; Call JA; Zhou Y; Terry K; O'hayer K; Lorusso PM, 2025, 'First results from a phase I trial of SNV1521, a next generation, CNS-penetrant, PARP1-selective inhibitor in patients (pts) with molecularly selected advanced solid tumors', ANNALS OF ONCOLOGY, 36, http://dx.doi.org/10.1016/j.annonc.2025.08.1492

Nguyen JTT; Nindra U; Tang J; Hong JH; Zwieky W; Hong M; Killen A; Wilkinson K; Pal A; Teng C; Roohullah A; Wei J; Ng WL; Lemech C; Chua W, 2025, 'Measuring what matters: RECIST response does not predict HRQoL in early-phase trials', ANNALS OF ONCOLOGY, 36, http://dx.doi.org/10.1016/j.annonc.2025.10.1003

Liu JJ; Farrow M; Hsing S; Cosman R; Lemech C; Teng C; Pal A; Nindra U; Parsonson A; Park JJW; Underhill CR; Hui MN; Nagrial A; Jain SS; Joshua AM, 2025, 'PANNA-COTA (Practical assessment of NECTA network assistance in cancer outpatient trials access): A prospective investigator-led trial using ctDNA to inform early phase trial matching', ANNALS OF ONCOLOGY, 36, http://dx.doi.org/10.1016/j.annonc.2025.08.1560

Song Y; Zhang J; Zhou K; Zhang L; Barve M; Lemech C; Li W; Cherng H-JJ; Huang H; Xie L; Zuniga R; Zhou C; Shen L; Yang S; Bishnoi S; Zhang Y; Wang J; Zhu X; Li E; Yang J, 2024, 'Safety and Efficacy in Patients with Advanced Lymphomas from a Global Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC', BLOOD, 144, pp. 1739 - 1740, http://dx.doi.org/10.1182/blood-2024-192979

Hayes AG; Jonker B; Teng C; Lemech C; Killen AJ; Sim HW; McCormack AI, 2024, 'Approach to the Patient: New Era Emerges for Craniopharyngioma Management', Journal of Clinical Endocrinology and Metabolism, 109, pp. 2986 - 2996, http://dx.doi.org/10.1210/clinem/dgae503

Armstrong AJ; Geva R; Chung HC; Lemech C; Miller WH; Hansen AR; Lee JS; Tsai F; Solomon BJ; Kim TM; Rolfo C; Giranda V; Ren Y; Liu F; Kandala B; Freshwater T; Wang JS, 2024, 'Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial(Investigational New Drugs, (2024), 42, (145-159), 10.1007/s10637-023-01410-2)', Investigational New Drugs, 42, pp. 340 - 341, http://dx.doi.org/10.1007/s10637-024-01444-0

Wahlroos S; Teng C; Tran B; Voskoboynik M; Gan HK; Spencer A; Kudva A; Song M; Lynch K; Yu Z; Desai J; Lemech CR, 2024, 'Results of a first-in-human, dose-escalation phase 1 study of the ERK1/2 inhibitor ATG-017 in patients with advanced solid tumors.', Journal of Clinical Oncology, 42, pp. e15114 - e15114, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e15114

Frentzas S; Mislang ARA; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG, 2024, 'Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors', Journal for Immunotherapy of Cancer, 12, http://dx.doi.org/10.1136/jitc-2023-008037

Dorff T; Horvath LG; Autio K; Bernard-Tessier A; Rettig MB; Machiels JP; Bilen MA; Lolkema MP; Adra N; Rottey S; Greil R; Matsubara N; Tan DSW; Wong A; Uemura H; Lemech C; Meran J; Yu Y; Minocha M; McComb M; Penny HL; Gupta V; Hu X; Jurida G; Kouros-Mehr H; Janat-Amsbury MM; Eggert T; Tran B, 2024, 'A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer', Clinical Cancer Research, 30, pp. 1488 - 1500, http://dx.doi.org/10.1158/1078-0432.CCR-23-2978

Cheng Y; Lisberg A; Lemech C; Abed A; Chaudhry A; Schmidt A; Lu X; Zhu Z; Gu W; Qiu Y; Shi R; Zhang B, 2024, 'Abstract CT165: A phase 1/2a, multicenter, open-label, first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1311 (a B7-H3-targeting ADC) in patients with advanced/metastatic solid tumors', Cancer Research, 84, pp. CT165 - CT165, http://dx.doi.org/10.1158/1538-7445.am2024-ct165

Atkinson VG; Antras JF; Bedard P; Brenner W; Brown J; Lemech CR; Lloyd P; Margolin K; Mathew M; Park JJ; Thomas S; Twardowski P; Gardner H; Prawira A; Coello M; Ebrahimimizadeh W; To MD; Merchant R; Karanam SM; Yavari A; Siu LL; Tawbi HA; Ascierto PA, 2024, 'Abstract CT259: Results from monotherapy dose escalation of MDNA11, a long-acting IL-2 superkine, in a phase 1/2 trial show evidence of single-agent activity in advanced solid tumors', Cancer Research, 84, pp. CT259 - CT259, http://dx.doi.org/10.1158/1538-7445.am2024-ct259

Armstrong AJ; Geva R; Chung HC; Lemech C; Miller WH; Hansen AR; Lee JS; Tsai F; Solomon BJ; Kim TM; Rolfo C; Giranda V; Ren Y; Liu F; Kandala B; Freshwater T; Wang JS, 2024, 'CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial', Investigational New Drugs, 42, pp. 145 - 159, http://dx.doi.org/10.1007/s10637-023-01410-2

Tran B; Voskoboynik M; Bendell J; Gutierrez M; Lemech C; Day D; Frentzas S; Garrido-Laguna I; Standifer N; Wang F; Ferte C; Wang Y; Das M; Carneiro BA, 2024, 'A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors', Immunotherapy, 16, pp. 759 - 774, http://dx.doi.org/10.1080/1750743X.2024.2359359

Lemech CR; Zuniga R; Barve MA; Song Y; Zhang J; Zhou K; Zhang L; Shen L; Bishnoi S; Cherng HJJ; Zhou C; Li W; Wang J; Zhu X; Zhu D; Li F; Shen Z; Yang J, 2024, 'A phase 1a/b, multi-regional, first-in-human study of CS5001, a novel anti-ROR1 ADC, in patients with advanced solid tumors and lymphomas.', Journal of Clinical Oncology, 42, pp. 3023 - 3023, http://dx.doi.org/10.1200/JCO.2024.42.16_suppl.3023

Thoms J; Hampton H; Yan F; Davidson S; Joshi S; Sarowar C; Lim XY; Nunez A; Kakadia P; Saw J; Bhuyan GS; Zou X; Ghodousi E; Jolly C; Koch F; Vafaee F; Pickford R; Raftery M; Hough S; Buckland G; Bailey M; Ghodke Y; Absar N; Vaughan L; Pasalic L; Fong C; Kenealy M; Hiwase D; Stoddart R; Mohammed S; Lee L; Passam F; Spring K; Skarratt K; Rebeiro P; Larsen S; Presgrave P; Stevenson W; Ling S; Tiley C; Fuller S; Roncolato F; Enjeti A; Hoenemann D; Lemech C; Curtis D; Bohlander S; Olivier J; Hertzberg M; Unnikrishnan A; Polizotto M; Pimanda J, 2024, '3178 – LONGITUDINAL DRUG INCORPORATION, CLONAL COMPOSITION, AND DNA METHYLATION DYNAMICS IN MDS/CMML PATIENTS TREATED WITH AZA', Experimental Hematology, 137, pp. 104498 - 104498, http://dx.doi.org/10.1016/j.exphem.2024.104498

Lemech C; Sun Y; Nagrial A; Wu X; Morris M; Ning F; Yang J; Pan Y; Cai J; Lu P; Zhang T; Qiu F; Hu C; Zhang M; Liu Z; Han G; Nie J; Teng C; Zhou H; Day D, 2024, '345MO IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): Results from a phase I study', Annals of Oncology, 35, pp. S360 - S360, http://dx.doi.org/10.1016/j.annonc.2024.08.293

Gong J; Lemech C; Day D; Shan J; Morris M; Nagrial A; Chen M; Huang X; Zong H; Wang N; Yang Y; Yi T; Li W; Zhuang Z; Li Z; Liu Z; Luo Y; Zhang Y; Zhou H; Shen L, 2024, '576P Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: Results from a phase I study', Annals of Oncology, 35, pp. S467 - S468, http://dx.doi.org/10.1016/j.annonc.2024.08.645

Cheng Y; Wu L; Parsonson A; Amin H; Shi J; Lemech C; Sun Y; Schmidt A; Lv D; Li M; Zheng T; Chaudhry A; Gandhi C; Wang Q; Motino DAM; Abed A; Tibes R; Lu X; Gu V; Lisberg AE, 2024, '57O A phase I/II multicenter, first-in-human study of DB-1311/BNT324 (a novel B7H3 ADC) in patients with advanced solid tumors', Annals of Oncology, 35, pp. S1426 - S1426, http://dx.doi.org/10.1016/j.annonc.2024.10.078

Lemech C; Luke JJ; Falchook GS; Mckean M; Kichenadasse G; Teng C; Vandross AL; Salkeni MA; Atkinson VG; Liu JJ; Kennedy AM; Clark J; Ryan M; Schmidt-Kittler O; Steinhubel D; Wages D; Komarnitsky P; Puzanov I, 2024, 'A phase I, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations', ANNALS OF ONCOLOGY, 35, pp. S528 - S529, http://dx.doi.org/10.1016/j.annonc.2024.08.744

Mercuri FA; White S; McQuilten HA; Lemech C; Mynhardt S; Hari R; Zhang P; Kruger N; McLachlan G; Miller BE; West NP; Tal-Singer R; Demaison C, 2024, 'Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology.', ERJ Open Res, 10, http://dx.doi.org/10.1183/23120541.00199-2024

Lemech C; Kichenadasse G; Teng C; Nagrial A; Richardson G; Humphries TG; Killen AJ; Joshua A; Liu JJ; Churchill M; Barnett M; Cioffi M; Cosman R, 2024, 'MYE Symphony: A first-in-human study to investigate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the in vivo mRNA CAR therapy, MT-302, targeting TROP2 in adults with advanced epithelial tumors', ANNALS OF ONCOLOGY, 35, pp. S528 - S528, http://dx.doi.org/10.1016/j.annonc.2024.08.742

Lee S-H; Han J-Y; Lee KH; Lee G-W; Lemech C; Millward M; Roohullah A; Le X; Park K; Choi JY; Kim NY; Im S; Rajasekaran N; Park KE; Lee S; Moon H; Hwang S; Shin Y; Lee DH, 2023, 'Abstract B042: Efficacy and safety outcomes of ABN401 in NSCLC patients with MET Exon 14 Skipping: A clinically relevant subgroup analysis', Molecular Cancer Therapeutics, 22, pp. B042 - B042, http://dx.doi.org/10.1158/1535-7163.targ-23-b042

Day D; Park JJ; Coward J; Markman B; Lemech C; Kuo JC; Prawira A; Brown MP; Bishnoi S; Kotasek D; Strother RM; Cosman R; Su R; Ma Y; Yue Z; Hu HH; Wu R; Li P; Tse AN, 2023, 'A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer', British Journal of Cancer, 129, pp. 1608 - 1618, http://dx.doi.org/10.1038/s41416-023-02431-7

Wynne CJ; Cole A; Lemech C; Wang G; Zhang Y; Chen B; Wang M; Li B; Xia M; Sinclair R, 2023, 'Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study', Dermatology and Therapy, 13, pp. 2357 - 2373, http://dx.doi.org/10.1007/s13555-023-01010-1

Back to profile page